Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Verve Therapeutics Inc (VERV)

Verve Therapeutics Inc (VERV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 992,162
  • Shares Outstanding, K 89,143
  • Annual Sales, $ 32,330 K
  • Annual Income, $ -198,710 K
  • EBIT $ -208 M
  • EBITDA $ -214 M
  • 60-Month Beta 2.23
  • Price/Sales 30.60
  • Price/Cash Flow N/A
  • Price/Book 2.10
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.11
  • Most Recent Earnings $-0.35 on 05/14/25
  • Next Earnings Date 08/14/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.70
  • Number of Estimates 4
  • High Estimate -0.59
  • Low Estimate -0.76
  • Prior Year -0.59
  • Growth Rate Est. (year over year) -18.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.90 +2.11%
on 07/18/25
11.34 -1.85%
on 07/02/25
-0.04 (-0.36%)
since 06/24/25
3-Month
3.89 +186.12%
on 05/29/25
11.40 -2.37%
on 06/17/25
+5.35 (+92.56%)
since 04/24/25
52-Week
2.86 +289.16%
on 04/09/25
11.40 -2.37%
on 06/17/25
+4.05 (+57.20%)
since 07/24/24

Most Recent Stories

More News
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

INDIANAPOLIS , July 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV)....

LLY : 1,063.56 (-1.99%)
VERV : 11.13 (+0.27%)
Lilly and Verve announce expiration of Verve tender offer

INDIANAPOLIS , July 24, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to purchase all of the...

LLY : 1,063.56 (-1.99%)
VERV : 11.13 (+0.27%)
3 Bullish Biotech Stocks With Explosive Growth Trends

These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies

URGN : 21.25 (-9.46%)
VERV : 11.13 (+0.27%)
NKTR : 39.71 (-4.17%)
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook

Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.

GOGO : 5.24 (+3.15%)
LLY : 1,063.56 (-1.99%)
KSS : 20.54 (-5.61%)
VERV : 11.13 (+0.27%)
NTLA : 10.38 (-1.33%)
Small Cap News Movers: Your Daily Digest of Stocks Making Moves on Market News

The past week has seen a flurry of activity across various sectors, with several small- and mid-cap stocks delivering notable gains and drawing significant investor attention. From healthcare innovators...

WGS : 135.38 (-1.52%)
GEOS : 21.89 (+7.83%)
NNNN : 34.99 (+7.73%)
CDTX : 221.38 (+0.03%)
VERV : 11.13 (+0.27%)
EYEN : 15.82 (+49.81%)
A $1.3 Billion Reason to Buy Eli Lilly Stock Now

Eli Lilly has just acquired gene-editing company Verve Therapeutics.

LLY : 1,063.56 (-1.99%)
VERV : 11.13 (+0.27%)
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week

NFLX : 89.46 (-1.18%)
NVDA : 184.86 (-0.10%)
LLY : 1,063.56 (-1.99%)
VERV : 11.13 (+0.27%)
Wall Street ends mixed after the Fed says it's still waiting to see the effects of Trump's tariffs

U.S. stocks drifted to a mixed finish after the Federal Reserve indicated it may cut interest rates twice this year, though it’s far from certain about that

ENPH : 35.22 (-0.59%)
$SPX : 6,966.28 (+0.65%)
$DOWI : 49,504.07 (+0.48%)
VERV : 11.13 (+0.27%)
$IUXX : 25,766.26 (+1.02%)
NUE : 163.77 (-2.45%)
Stocks slump and oil prices jump as Trump urges Iran's unconditional surrender

U.S. stocks slumped under the weight of a jump for the price of oil

ENPH : 35.22 (-0.59%)
LMT : 542.92 (+4.72%)
FSLR : 238.66 (-3.09%)
NOC : 618.82 (+4.74%)
$SPX : 6,966.28 (+0.65%)
$DOWI : 49,504.07 (+0.48%)
VERV : 11.13 (+0.27%)
$IUXX : 25,766.26 (+1.02%)
Stocks Tumble and Oil Surges on Middle East Jitters

The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.84%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.00%. June E-mini...

UAL : 117.32 (+1.60%)
MPC : 176.17 (-0.51%)
DHI : 157.28 (+7.80%)
CVX : 162.11 (+1.80%)
MRK : 110.53 (-0.41%)
LVS : 58.95 (-4.77%)
$IUXX : 25,766.26 (+1.02%)
ALKS : 29.66 (+0.20%)
PFE : 25.48 (+0.75%)
ZNH26 : 112-070s (-0.03%)
OXY : 42.86 (-0.86%)
ESH26 : 7,005.00s (+0.62%)

Business Summary

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's lead product candidate includes VERVE-101. Verve Therapeutics is based in CAMBRIDGE,...

See More

Key Turning Points

3rd Resistance Point 11.37
2nd Resistance Point 11.31
1st Resistance Point 11.22
Last Price 11.13
1st Support Level 11.07
2nd Support Level 11.01
3rd Support Level 10.92

See More

52-Week High 11.40
Last Price 11.13
Fibonacci 61.8% 8.14
Fibonacci 50% 7.13
Fibonacci 38.2% 6.12
52-Week Low 2.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar